✨ Free AI Report
I-Mab Biopharma (NovaBridge Biosciences): Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research I-Mab Biopharma (NovaBridge Biosciences)
Company Research

I-Mab Biopharma (NovaBridge Biosciences): Business Overview, Financials & Competitive Analysis

I-Mab Biopharma (NovaBridge Biosciences) scores 7/10 on the AskCyborg Cyborg Score (Strong). Late-stage immuno-oncology platform with validated lead asset pursuing Phase 2 gastric cancer studies and expanding into multiple cancer types with strengthened financial position. Lead asset givastomig demonstrates strong clinical efficacy (83% ORR in combination studies), with Phase 2 initiation planned Q1 2026. Company has extended cash runway through.

What is I-Mab Biopharma (NovaBridge Biosciences)'s industry? I-Mab Biopharma (NovaBridge Biosciences) (i-mabbiopharma.com) operates in Biopharmaceutical/Immuno-Oncology. AskCyborg classifies I-Mab Biopharma (NovaBridge Biosciences) under Biopharmaceutical/Immuno-Oncology in its company registry.

I-Mab is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics...

7/ 10Strong

Cyborg Score thesis

Late-stage immuno-oncology platform with validated lead asset pursuing Phase 2 gastric cancer studies and expanding into multiple...

Read the full analyst-debate transcript →
Industry Biopharmaceutical/Immuno-Oncology
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest I-Mab Biopharma (NovaBridge Biosciences) Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for I-Mab Biopharma (NovaBridge Biosciences)

AskCyborg analysts argue the bull and bear cases for I-Mab Biopharma (NovaBridge Biosciences) across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
I-Mab Biopharma (NovaBridge Biosciences) OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

I-Mab Biopharma (NovaBridge Biosciences) Overview

Pro stress-test →

I-Mab is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology. The company recently underwent a strategic transformation, rebranding to NovaBridge Biosciences and planning a dual NASDAQ-Hong Kong listing.

Strategic Profile

Pro stress-test →

The company emphasizes a focus on precision immuno-oncology, particularly targeting mechanisms such as Claudin 18.2, 4-1BB, PD-L1, and CD73 in solid tumors. I-Mab's innovative pipeline is driven by internal R&D's Fast-to-Proof-of-Concept, Fast-to-Market development strategies, and through global partnerships.

Competitive Landscape

Pro stress-test →

Claudin 18.2 is emerging as a key therapeutic target for gastric cancer, with givastomig positioned as a bispecific antibody competing in this space. The company competes with other immuno-oncology developers pursuing similar targets and mechanism combinations, with competitive advantage derived from its bispecific antibody engineering platform and partnership network.

Industry Context

I-Mab Biopharma (NovaBridge Biosciences) operates in Biopharmaceutical/Immuno-Oncology.

Key facts

Headquarters: Rockville, Maryland, USA

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on I-Mab Biopharma (NovaBridge Biosciences).

  • Lead asset givastomig (CLDN18.2 x 4-1BB bispecific) shows 83% objective response rate in Phase 1b combination studies targeting gastric cancer, with global Phase 2 launch planned Q1 2026
  • Company rebranded to NovaBridge Biosciences in October 2025 and now trades under ticker NBP on NASDAQ, with plans for Hong Kong dual listing
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • October 2025Strategic transformation: Rebranding to NovaBridge Biosciences, ticker changed from IMAB to NBP, Hong Kong IPO planning announced
  • October 2025Announced acquisition of VIS-101 ophthalmology program and formation of Visara subsidiary with $37M capital infusion
  • +2 moreTrack every material event for I-Mab Biopharma (NovaBridge Biosciences) as it happens. Explore monitoring →
Get alerted when I-Mab Biopharma (NovaBridge Biosciences) has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Astellas/Syneos Health Claudin 18.2 ProgramCLDN18.2-targeting gastric cancer therapy→4-1BB agonist programsAlternative 4-1BB immunotherapy approaches→Anti-CD73 therapiesCD73-targeting immuno-oncology agents→

Compare I-Mab Biopharma (NovaBridge Biosciences) with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

I-Mab Biopharma (NovaBridge Biosciences) operates in Biopharmaceutical/Immuno-Oncology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical/Immuno-Oncology research →
NEW · MCP server

Ask your AI assistant about I-Mab Biopharma (NovaBridge Biosciences)

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare I-Mab Biopharma (NovaBridge Biosciences) and its top competitor on Cyborg Score”
“What did I-Mab Biopharma (NovaBridge Biosciences) do this quarter?”
“Is I-Mab Biopharma (NovaBridge Biosciences) a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does I-Mab Biopharma (NovaBridge Biosciences) do?+
I-Mab is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics...
What is I-Mab Biopharma (NovaBridge Biosciences)'s Cyborg Score?+
I-Mab Biopharma (NovaBridge Biosciences) has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are I-Mab Biopharma (NovaBridge Biosciences)'s main competitors?+
Named competitors include Astellas/Syneos Health Claudin 18.2 Program, 4-1BB agonist programs, Anti-CD73 therapies. The full competitive landscape is in the AskCyborg report.
How can I get the full I-Mab Biopharma (NovaBridge Biosciences) research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the I-Mab Biopharma (NovaBridge Biosciences) research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track I-Mab Biopharma (NovaBridge Biosciences) over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score